BIO-TECHNE Corp — Director's Dealing 2022

Aug 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-08-15

Reporting Person: Kummeth Charles R. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-15	Restricted Stock Units	$	A	13225	Acquired		Common Stock (13225)	Direct
2022-08-15	Stock Options (Right to Buy)	$378.08	A	300000	Acquired	2029-08-15	Common Stock (300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	240403	Direct
Common Stock	100	Indirect
Common Stock	100	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$106.5900	2023-08-18	Common Stock (256010)	256010	Direct
Stock Options (Right to Buy)	$125.0500	2024-08-09	Common Stock (194771)	194771	Direct
Stock Options (Right to Buy)	$177.3200	2025-08-08	Common Stock (90334)	90334	Direct
Stock Options (Right to Buy)	$177.3200	2025-08-08	Common Stock (60222)	60222	Direct
Stock Options (Right to Buy)	$190.4100	2026-08-07	Common Stock (85725)	85725	Direct
Stock Options (Right to Buy)	$190.4100	2026-08-07	Common Stock (57150)	57150	Direct
Restricted Stock Units	$		Common Stock (12879)	12879	Direct
Stock Options (Right to Buy)	$267.8700	2027-08-05	Common Stock (57442)	57442	Direct
Stock Options (Right to Buy)	$267.8700	2027-08-05	Common Stock (38295)	38295	Direct
Stock Options (Right to Buy)	$267.8700	2027-08-05	Common Stock (16650)	16650	Direct
Stock Options (Right to Buy)	$267.8700	2027-08-05	Common Stock (16650)	16650	Direct
Restricted Stock Units	$		Common Stock (8016)	8016	Direct
Stock Options (Right to Buy)	$481.8200	2028-08-06	Common Stock (31315)	31315	Direct
Stock Options (Right to Buy)	$481.8200	2028-08-06	Common Stock (20876)	20876	Direct

Footnotes

F1: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024.

F2: Fully exercisable.

F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F4: 4,408 shares vest on each of 8/15/2023 and 8/15/2025, and 4,409 shares vest on 8/15/2024.

F5: 150,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 150,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

F7: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F8: Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.

F9: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F10: Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.

F11: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F12: Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.